Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label, 2-Cohort Study of Nimotuzumab 400 mg Weekly Plus Irinotecan (Cohort 1) and Nimotuzumab 400 mg Every 2 Weeks Plus Irinotecan (Cohort 2) in Patients With Irinotecan-Refractory Metastatic Colorectal Cancer

NCT00493857 is registered in ClinicalTrials.gov with YM BioSciences as lead sponsor.

NCT NCT00493857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00493857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label, 2-Cohort Study of Nimotuzumab 400 mg Weekly Plus Irinotecan (Cohort 1) and Nimotuzumab 400 mg Every 2 Weeks Plus Irinotecan (Cohort 2) in Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
Lead sponsor
YM BioSciences
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2007
Completion date
December 31, 2008
Enrollment
100 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer